HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Dietary Supplements Wellness

Consumer Health Products Regulatory Roundup

This article was originally published in The Tan Sheet

  • News

Executive Summary

Weight loss product firms touch all the bases in advertising violations; a scoop too small in children's nutritional; and another sibutramine-spiked supplement found.

You may also be interested in...



FTC Litigation, Hormel, NuSkin Recalls: Health And Wellness Industry News Roundup

$500,000 fine in $1.3m FTC judgement; and Hormel and NuSkin nutritional products recalled.

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.

Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch

The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.

Table

View full table

Topics

Tags:
Dietary Supplements Wellness
Latest Headlines

US Health And Wellness Executive Decisions: Perrigo, Nestle, Flexpower Health, Herbalife, More

FDA’s OTC Monograph User Fees Are Existential Threat To Small Contract Manufacturers, Cosmetics Brands

ECHA Committees Get Started On PFAS Opinions, Armed With More Than 5,600 Comments

‘The Power Of Persuasion’: FDA Ombudsman Discusses Her Role

See All
UsernamePublicRestriction

Register

RS108929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By